Flag of the European Union EU Clinical Trials Register Help

Clinical trials

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

  • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).


    The EU Clinical Trials Register currently displays   44334   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     

    < Back to search results

    Download PDF

    Clinical Trial Results:
    A Phase 2b Randomized, Double-Masked, Controlled Trial to Assess the Safety and Efficacy of Intravitreous Administration of Zimura™ (Anti-C5 Aptamer) in Subjects with Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration

    Summary
    EudraCT number
    2015-003991-56
    Trial protocol
    HU   LV   EE   HR  
    Global end of trial date
    23 Apr 2020

    Results information
    Results version number
    v1(current)
    This version publication date
    15 Jul 2022
    First version publication date
    15 Jul 2022
    Other versions

    Trial information

    Close Top of page
    Trial identification
    Sponsor protocol code
    OPH2003
    Additional study identifiers
    ISRCTN number
    -
    US NCT number
    NCT02686658
    WHO universal trial number (UTN)
    -
    Sponsors
    Sponsor organisation name
    IVERIC bio, Inc.
    Sponsor organisation address
    1249 South River Road, Suite 107, Cranbury, United States, NJ 08512
    Public contact
    Medical Director, IVERIC bio, Inc., clinicaltrials@ivericbio.com
    Scientific contact
    Medical Director, IVERIC bio, Inc., clinicaltrials@ivericbio.com
    Paediatric regulatory details
    Is trial part of an agreed paediatric investigation plan (PIP)
    No
    Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?
    No
    Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?
    No
    Results analysis stage
    Analysis stage
    Final
    Date of interim/final analysis
    19 May 2020
    Is this the analysis of the primary completion data?
    Yes
    Primary completion date
    15 Oct 2019
    Global end of trial reached?
    Yes
    Global end of trial date
    23 Apr 2020
    Was the trial ended prematurely?
    No
    General information about the trial
    Main objective of the trial
    The objectives of this study were to evaluate the safety and efficacy of Zimura™ intravitreal administration when administered in subjects with geographic atrophy secondary to age-related macular degeneration (AMD). The study design was based on the screening study methodology presented in Fleming and Richardson 2004. By pre-specification, Screening analysis was performed to assess whether the effect of Zimura on the mean rate of GA growth was plausibly more efficacious (or reliably more efficacious) than that of the Sham control on the mean rate of GA growth over 12 months.
    Protection of trial subjects
    Before initiation of the study, the protocol and the patient informed consent provisions were reviewed and approved by the appropriate Independent Ethics Committees (IECs) or Institutional Review Boards (IRBs) for each of the centers involved in the study according to national or local regulations and in accordance with the United States (US) Food and Drug Administration (FDA) Title 21, Code of Federal Regulations Parts 56.107 through 56.115, the International Conference on Harmonisation Good Clinical Practice (ICH-GCP) guidelines (Committee for Proprietary Medicinal Products/ICH/135/95), or local laws. Study initiation at each site began only after receiving written approval from the IEC/IRB. The protocol amendments were reviewed and approved by the appropriate IECs or IRBs for each of the centers. The study was conducted in full compliance with the principles of the Declaration of Helsinki, as adopted in 1964 by the 18th World Medical Assembly and amended in Tokyo, Venice, Hong Kong, South Africa, and Scotland, and in compliance with the respective law and regulations of the country in which the research was conducted. In addition, the study was performed in line with the principles outlined in the Guideline for GCP (ICH E6), the ICH Tripartite Guideline (May 1997), and US FDA regulations. Prior to study entry, all patients were informed fully of the nature and aims of the study. Ample time was provided for patients to read the patient information sheet and ask any questions regarding the investigational drug. Patients were informed that their participation was voluntary and that they could withdraw from the study at any time for any reason without incurring any penalty or withholding of treatment on the part of the investigator. Before receiving any treatment related to this study, all patients provided their written informed consent.
    Background therapy
    -
    Evidence for comparator
    -
    Actual start date of recruitment
    20 Jan 2016
    Long term follow-up planned
    No
    Independent data monitoring committee (IDMC) involvement?
    Yes
    Population of trial subjects
    Number of subjects enrolled per country
    Country: Number of subjects enrolled
    Croatia: 5
    Country: Number of subjects enrolled
    Czechia: 9
    Country: Number of subjects enrolled
    Hungary: 42
    Country: Number of subjects enrolled
    Latvia: 4
    Country: Number of subjects enrolled
    United States: 218
    Country: Number of subjects enrolled
    Israel: 8
    Worldwide total number of subjects
    286
    EEA total number of subjects
    60
    Number of subjects enrolled per age group
    In utero
    0
    Preterm newborn - gestational age < 37 wk
    0
    Newborns (0-27 days)
    0
    Infants and toddlers (28 days-23 months)
    0
    Children (2-11 years)
    0
    Adolescents (12-17 years)
    0
    Adults (18-64 years)
    24
    From 65 to 84 years
    190
    85 years and over
    72

    Subject disposition

    Close Top of page
    Recruitment
    Recruitment details
    -

    Pre-assignment
    Screening details
    Inclusion: age ≥50 years, geographic atrophy (GA) secondary to age-related macular degeneration (AMD) Exclusion: evidence of choroidal neovascularization (CNV) in either eye, GA secondary to any condition other than AMD, prior treatment for AMD or any prior intravitreal treatment

    Period 1
    Period 1 title
    Overall (overall period)
    Is this the baseline period?
    Yes
    Allocation method
    Randomised - controlled
    Blinding used
    Double blind
    Roles blinded
    Subject, Investigator, Assessor

    Arms
    Are arms mutually exclusive
    No

    Arm title
    Zimura 1 mg (part 1)
    Arm description
    -
    Arm type
    Experimental

    Investigational medicinal product name
    avacincaptad pegol
    Investigational medicinal product code
    ARC1905
    Other name
    Zimura
    Pharmaceutical forms
    Solution for injection
    Routes of administration
    Intravitreal use
    Dosage and administration details
    Monthly administration of Zimura 1 mg/eye.

    Arm title
    Zimura 2 mg (Combined part 1 + part 2)
    Arm description
    -
    Arm type
    Experimental

    Investigational medicinal product name
    avacincaptad pegol
    Investigational medicinal product code
    ARC1905
    Other name
    Zimura
    Pharmaceutical forms
    Solution for injection
    Routes of administration
    Intravitreal use
    Dosage and administration details
    Part 1: Monthly administration of Zimura 2 mg/eye Part 2: Monthly administration of Zimura 2mg/eye plus sham to maintain study masking

    Arm title
    Zimura 4 mg (part 2)
    Arm description
    -
    Arm type
    Experimental

    Investigational medicinal product name
    avacincaptad pegol
    Investigational medicinal product code
    ARC1905
    Other name
    Zimura
    Pharmaceutical forms
    Solution for injection
    Routes of administration
    Intravitreal use
    Dosage and administration details
    Monthly administration of Zimura 4 mg/eye (administered as 2 IVT injections of Zimura 2mg/eye).

    Arm title
    Sham (Combined part 1 + part 2)
    Arm description
    -
    Arm type
    Sham injection

    Investigational medicinal product name
    No investigational medicinal product assigned in this arm
    Arm title
    Sham (part 2)
    Arm description
    -
    Arm type
    Sham injection

    Investigational medicinal product name
    No investigational medicinal product assigned in this arm
    Number of subjects in period 1
    Zimura 1 mg (part 1) Zimura 2 mg (Combined part 1 + part 2) Zimura 4 mg (part 2) Sham (Combined part 1 + part 2) Sham (part 2)
    Started
    26
    67
    83
    110
    84
    Completed
    24
    55
    58
    96
    75
    Not completed
    2
    12
    25
    14
    9
         Consent withdrawn by subject
    1
    6
    13
    8
    5
         Physician decision
    -
    1
    2
    1
    1
         Adverse event, non-fatal
    -
    -
    1
    1
    -
         Death
    -
    -
    1
    1
    1
         Sponsor decision
    1
    5
    8
    2
    2
         Lost to follow-up
    -
    -
    -
    1
    -

    Baseline characteristics

    Close Top of page
    Baseline characteristics reporting groups
    Reporting group title
    Zimura 1 mg (part 1)
    Reporting group description
    -

    Reporting group title
    Zimura 2 mg (Combined part 1 + part 2)
    Reporting group description
    -

    Reporting group title
    Zimura 4 mg (part 2)
    Reporting group description
    -

    Reporting group title
    Sham (Combined part 1 + part 2)
    Reporting group description
    -

    Reporting group title
    Sham (part 2)
    Reporting group description
    -

    Reporting group values
    Zimura 1 mg (part 1) Zimura 2 mg (Combined part 1 + part 2) Zimura 4 mg (part 2) Sham (Combined part 1 + part 2) Sham (part 2) Total
    Number of subjects
    26 67 83 110 84 286
    Age categorical
    Units: Subjects
        In utero
    0 0 0 0 0 0
        Preterm newborn infants (gestational age < 37 wks)
    0 0 0 0 0 0
        Newborns (0-27 days)
    0 0 0 0 0 0
        Infants and toddlers (28 days-23 months)
    0 0 0 0 0 0
        Children (2-11 years)
    0 0 0 0 0 0
        Adolescents (12-17 years)
    0 0 0 0 0 0
        Adults (18-64 years)
    3 10 5 6 4 24
        From 65-84 years
    22 34 57 77 60 190
        85 years and over
    1 23 21 27 20 72
    Age continuous
    Units: years
        arithmetic mean (standard deviation)
    73.8 ( 7.97 ) 78.8 ( 10.22 ) 79.2 ( 8.31 ) 78.2 ( 8.82 ) 78.2 ( 8.98 ) -
    Gender categorical
    Units: Subjects
        Female
    15 45 58 79 61 197
        Male
    11 22 25 31 23 89
    Ethnicity
    Units: Subjects
        Not Hispanic or Latino
    25 66 82 108 83 281
        Hispanic or Latino
    1 1 1 2 1 5
    Race
    Units: Subjects
        American Indian / Alaska Native
    0 0 0 0 0 0
        Black or African American
    0 0 0 1 1 1
        Asian
    1 0 0 0 0 1
        Native Hawaiian / Pacific Islander
    0 0 0 0 0 0
        White
    25 67 82 107 82 281
        Other
    0 0 1 2 1 3

    End points

    Close Top of page
    End points reporting groups
    Reporting group title
    Zimura 1 mg (part 1)
    Reporting group description
    -

    Reporting group title
    Zimura 2 mg (Combined part 1 + part 2)
    Reporting group description
    -

    Reporting group title
    Zimura 4 mg (part 2)
    Reporting group description
    -

    Reporting group title
    Sham (Combined part 1 + part 2)
    Reporting group description
    -

    Reporting group title
    Sham (part 2)
    Reporting group description
    -

    Primary: Change in Geographic Atrophy

    Close Top of page
    End point title
    Change in Geographic Atrophy [1]
    End point description
    Mean rate of change in GA measured by fundus autofluorescence (FAF)
    End point type
    Primary
    End point timeframe
    From baseline to Month 12.
    Notes
    [1] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
    Justification: Comparison of Zimura 1 mg vs. Sham was not part of the primary endpoint.
    End point values
    Zimura 2 mg (Combined part 1 + part 2) Zimura 4 mg (part 2) Sham (Combined part 1 + part 2) Sham (part 2)
    Number of subjects analysed
    67
    83
    110
    84
    Units: rate
    least squares mean (standard error)
        Month 12
    0.292 ( 0.077 )
    0.321 ( 0.074 )
    0.402 ( 0.075 )
    0.444 ( 0.072 )
    Statistical analysis title
    Zimura 2 mg compared to Sham - Month 12
    Comparison groups
    Zimura 2 mg (Combined part 1 + part 2) v Sham (Combined part 1 + part 2)
    Number of subjects included in analysis
    177
    Analysis specification
    Pre-specified
    Analysis type
    superiority
    P-value
    = 0.0072
    Method
    Mixed models analysis
    Parameter type
    Mean difference (final values)
    Point estimate
    0.11
    Confidence interval
         level
    95%
         sides
    2-sided
         lower limit
    0.03
         upper limit
    0.19
    Statistical analysis title
    Zimura 4 mg compared to Sham - Month 12
    Comparison groups
    Zimura 4 mg (part 2) v Sham (part 2)
    Number of subjects included in analysis
    167
    Analysis specification
    Pre-specified
    Analysis type
    superiority
    P-value
    = 0.0051
    Method
    Mixed models analysis
    Parameter type
    Mean difference (final values)
    Point estimate
    0.124
    Confidence interval
         level
    95%
         sides
    2-sided
         lower limit
    0.038
         upper limit
    0.209

    Adverse events

    Close Top of page
    Adverse events information
    Timeframe for reporting adverse events
    From first dose of study drug until End of Study
    Assessment type
    Systematic
    Dictionary used for adverse event reporting
    Dictionary name
    MedDRA
    Dictionary version
    18.1
    Reporting groups
    Reporting group title
    Zimura 1 mg
    Reporting group description
    -

    Reporting group title
    Zimura 2 mg (Combined part 1 + part 2)
    Reporting group description
    -

    Reporting group title
    Zimura 4 mg
    Reporting group description
    -

    Reporting group title
    Sham (Combined part 1 + part 2)
    Reporting group description
    -

    Serious adverse events
    Zimura 1 mg Zimura 2 mg (Combined part 1 + part 2) Zimura 4 mg Sham (Combined part 1 + part 2)
    Total subjects affected by serious adverse events
         subjects affected / exposed
    3 / 26 (11.54%)
    12 / 67 (17.91%)
    21 / 83 (25.30%)
    28 / 110 (25.45%)
         number of deaths (all causes)
    1
    1
    1
    1
         number of deaths resulting from adverse events
    0
    1
    1
    0
    Neoplasms benign, malignant and unspecified (incl cysts and polyps)
    Bladder cancer
         subjects affected / exposed
    0 / 26 (0.00%)
    1 / 67 (1.49%)
    0 / 83 (0.00%)
    0 / 110 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Metastases to bone
         subjects affected / exposed
    0 / 26 (0.00%)
    0 / 67 (0.00%)
    1 / 83 (1.20%)
    0 / 110 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Prostate cancer stage IV
         subjects affected / exposed
    0 / 26 (0.00%)
    0 / 67 (0.00%)
    1 / 83 (1.20%)
    0 / 110 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Breast cancer
         subjects affected / exposed
    0 / 26 (0.00%)
    0 / 67 (0.00%)
    0 / 83 (0.00%)
    1 / 110 (0.91%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Lung cancer metastatic
         subjects affected / exposed
    0 / 26 (0.00%)
    0 / 67 (0.00%)
    0 / 83 (0.00%)
    1 / 110 (0.91%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Lung neoplasm malignant
         subjects affected / exposed
    0 / 26 (0.00%)
    0 / 67 (0.00%)
    0 / 83 (0.00%)
    1 / 110 (0.91%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Metastases to adrenals
         subjects affected / exposed
    0 / 26 (0.00%)
    0 / 67 (0.00%)
    0 / 83 (0.00%)
    1 / 110 (0.91%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Metastases to central nervous system
         subjects affected / exposed
    0 / 26 (0.00%)
    0 / 67 (0.00%)
    0 / 83 (0.00%)
    1 / 110 (0.91%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Pancreatic carcinoma metastatic
         subjects affected / exposed
    0 / 26 (0.00%)
    0 / 67 (0.00%)
    0 / 83 (0.00%)
    1 / 110 (0.91%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Vascular disorders
    Subclavian artery stenosis
         subjects affected / exposed
    0 / 26 (0.00%)
    0 / 67 (0.00%)
    0 / 83 (0.00%)
    1 / 110 (0.91%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    General disorders and administration site conditions
    Asthenia
         subjects affected / exposed
    0 / 26 (0.00%)
    1 / 67 (1.49%)
    0 / 83 (0.00%)
    0 / 110 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Non-cardiac chest pain
         subjects affected / exposed
    0 / 26 (0.00%)
    1 / 67 (1.49%)
    0 / 83 (0.00%)
    0 / 110 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Respiratory, thoracic and mediastinal disorders
    Chronic obstructive pulmonary disease
         subjects affected / exposed
    0 / 26 (0.00%)
    1 / 67 (1.49%)
    1 / 83 (1.20%)
    3 / 110 (2.73%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 4
    0 / 1
    0 / 3
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Pneumonia aspiration
         subjects affected / exposed
    0 / 26 (0.00%)
    0 / 67 (0.00%)
    1 / 83 (1.20%)
    1 / 110 (0.91%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 1
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Pneumothorax
         subjects affected / exposed
    0 / 26 (0.00%)
    0 / 67 (0.00%)
    0 / 83 (0.00%)
    1 / 110 (0.91%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Respiratory distress
         subjects affected / exposed
    0 / 26 (0.00%)
    0 / 67 (0.00%)
    0 / 83 (0.00%)
    1 / 110 (0.91%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Psychiatric disorders
    Anxiety
         subjects affected / exposed
    0 / 26 (0.00%)
    0 / 67 (0.00%)
    0 / 83 (0.00%)
    1 / 110 (0.91%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Hallucination
         subjects affected / exposed
    0 / 26 (0.00%)
    0 / 67 (0.00%)
    0 / 83 (0.00%)
    1 / 110 (0.91%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Injury, poisoning and procedural complications
    Femur fracture
         subjects affected / exposed
    0 / 26 (0.00%)
    1 / 67 (1.49%)
    1 / 83 (1.20%)
    1 / 110 (0.91%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
    0 / 1
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Fall
         subjects affected / exposed
    0 / 26 (0.00%)
    1 / 67 (1.49%)
    0 / 83 (0.00%)
    2 / 110 (1.82%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
    0 / 0
    0 / 2
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Hip fracture
         subjects affected / exposed
    0 / 26 (0.00%)
    0 / 67 (0.00%)
    1 / 83 (1.20%)
    0 / 110 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Rib fracture
         subjects affected / exposed
    0 / 26 (0.00%)
    0 / 67 (0.00%)
    1 / 83 (1.20%)
    0 / 110 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Road traffic accident
         subjects affected / exposed
    0 / 26 (0.00%)
    0 / 67 (0.00%)
    1 / 83 (1.20%)
    0 / 110 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    Ulna fracture
         subjects affected / exposed
    0 / 26 (0.00%)
    1 / 67 (1.49%)
    0 / 83 (0.00%)
    0 / 110 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Head injury
         subjects affected / exposed
    0 / 26 (0.00%)
    0 / 67 (0.00%)
    0 / 83 (0.00%)
    1 / 110 (0.91%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Upper limb fracture
         subjects affected / exposed
    0 / 26 (0.00%)
    0 / 67 (0.00%)
    0 / 83 (0.00%)
    1 / 110 (0.91%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Cardiac disorders
    Acute myocardial infarction
         subjects affected / exposed
    0 / 26 (0.00%)
    1 / 67 (1.49%)
    1 / 83 (1.20%)
    0 / 110 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Mitral valve stenosis
         subjects affected / exposed
    0 / 26 (0.00%)
    0 / 67 (0.00%)
    1 / 83 (1.20%)
    0 / 110 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Ventricular extrasystoles
         subjects affected / exposed
    1 / 26 (3.85%)
    0 / 67 (0.00%)
    0 / 83 (0.00%)
    0 / 110 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Cardiac failure congestive
         subjects affected / exposed
    0 / 26 (0.00%)
    0 / 67 (0.00%)
    0 / 83 (0.00%)
    1 / 110 (0.91%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Coronary artery disease
         subjects affected / exposed
    0 / 26 (0.00%)
    0 / 67 (0.00%)
    0 / 83 (0.00%)
    3 / 110 (2.73%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 3
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Nervous system disorders
    Cerebrovascular accident
         subjects affected / exposed
    1 / 26 (3.85%)
    1 / 67 (1.49%)
    1 / 83 (1.20%)
    1 / 110 (0.91%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 1
    0 / 1
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Cerebral infarction
         subjects affected / exposed
    0 / 26 (0.00%)
    1 / 67 (1.49%)
    0 / 83 (0.00%)
    0 / 110 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    Dizziness
         subjects affected / exposed
    0 / 26 (0.00%)
    0 / 67 (0.00%)
    1 / 83 (1.20%)
    0 / 110 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Ischaemic cerebral infarction
         subjects affected / exposed
    0 / 26 (0.00%)
    0 / 67 (0.00%)
    1 / 83 (1.20%)
    0 / 110 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Syncope
         subjects affected / exposed
    0 / 26 (0.00%)
    1 / 67 (1.49%)
    0 / 83 (0.00%)
    0 / 110 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Cerebral haemorrhage
         subjects affected / exposed
    0 / 26 (0.00%)
    0 / 67 (0.00%)
    0 / 83 (0.00%)
    1 / 110 (0.91%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Ischaemic stroke
         subjects affected / exposed
    0 / 26 (0.00%)
    0 / 67 (0.00%)
    0 / 83 (0.00%)
    1 / 110 (0.91%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Lumbar radiculopathy
         subjects affected / exposed
    0 / 26 (0.00%)
    0 / 67 (0.00%)
    0 / 83 (0.00%)
    1 / 110 (0.91%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Blood and lymphatic system disorders
    Iron deficiency anaemia
         subjects affected / exposed
    0 / 26 (0.00%)
    0 / 67 (0.00%)
    1 / 83 (1.20%)
    0 / 110 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Eye disorders
    Optic ischaemic neuropathy
         subjects affected / exposed
    0 / 26 (0.00%)
    1 / 67 (1.49%)
    0 / 83 (0.00%)
    0 / 110 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Retinal detachment
         subjects affected / exposed
    0 / 26 (0.00%)
    0 / 67 (0.00%)
    1 / 83 (1.20%)
    0 / 110 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Gastrointestinal disorders
    Colitis
         subjects affected / exposed
    0 / 26 (0.00%)
    0 / 67 (0.00%)
    1 / 83 (1.20%)
    0 / 110 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Gastrointestinal necrosis
         subjects affected / exposed
    0 / 26 (0.00%)
    0 / 67 (0.00%)
    1 / 83 (1.20%)
    0 / 110 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Lower gastrointestinal haemorrhage
         subjects affected / exposed
    1 / 26 (3.85%)
    0 / 67 (0.00%)
    0 / 83 (0.00%)
    0 / 110 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Upper gastrointestinal haemorrhage
         subjects affected / exposed
    0 / 26 (0.00%)
    1 / 67 (1.49%)
    0 / 83 (0.00%)
    0 / 110 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Abdominal hernia
         subjects affected / exposed
    0 / 26 (0.00%)
    0 / 67 (0.00%)
    0 / 83 (0.00%)
    1 / 110 (0.91%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Appendiceal mucocoele
         subjects affected / exposed
    0 / 26 (0.00%)
    0 / 67 (0.00%)
    0 / 83 (0.00%)
    1 / 110 (0.91%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Diarrhoea
         subjects affected / exposed
    0 / 26 (0.00%)
    0 / 67 (0.00%)
    0 / 83 (0.00%)
    1 / 110 (0.91%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Faecaloma
         subjects affected / exposed
    0 / 26 (0.00%)
    0 / 67 (0.00%)
    0 / 83 (0.00%)
    1 / 110 (0.91%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Gastrointestinal haemorrhage
         subjects affected / exposed
    0 / 26 (0.00%)
    0 / 67 (0.00%)
    0 / 83 (0.00%)
    1 / 110 (0.91%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Gastrooesophageal reflux disease
         subjects affected / exposed
    0 / 26 (0.00%)
    0 / 67 (0.00%)
    0 / 83 (0.00%)
    1 / 110 (0.91%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Large intestinal stenosis
         subjects affected / exposed
    0 / 26 (0.00%)
    0 / 67 (0.00%)
    0 / 83 (0.00%)
    1 / 110 (0.91%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Small intestinal obstruction
         subjects affected / exposed
    0 / 26 (0.00%)
    0 / 67 (0.00%)
    0 / 83 (0.00%)
    1 / 110 (0.91%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Hepatobiliary disorders
    Bile duct stone
         subjects affected / exposed
    0 / 26 (0.00%)
    0 / 67 (0.00%)
    1 / 83 (1.20%)
    0 / 110 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Cholelithiasis
         subjects affected / exposed
    0 / 26 (0.00%)
    1 / 67 (1.49%)
    0 / 83 (0.00%)
    0 / 110 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Cholecystitis
         subjects affected / exposed
    0 / 26 (0.00%)
    0 / 67 (0.00%)
    0 / 83 (0.00%)
    1 / 110 (0.91%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Musculoskeletal and connective tissue disorders
    Intervertebral disc protrusion
         subjects affected / exposed
    1 / 26 (3.85%)
    0 / 67 (0.00%)
    0 / 83 (0.00%)
    0 / 110 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Lumbar spinal stenosis
         subjects affected / exposed
    1 / 26 (3.85%)
    0 / 67 (0.00%)
    0 / 83 (0.00%)
    1 / 110 (0.91%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Back pain
         subjects affected / exposed
    0 / 26 (0.00%)
    0 / 67 (0.00%)
    0 / 83 (0.00%)
    1 / 110 (0.91%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Osteoarthritis
         subjects affected / exposed
    0 / 26 (0.00%)
    0 / 67 (0.00%)
    0 / 83 (0.00%)
    1 / 110 (0.91%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Infections and infestations
    Pneumonia
         subjects affected / exposed
    0 / 26 (0.00%)
    1 / 67 (1.49%)
    3 / 83 (3.61%)
    1 / 110 (0.91%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
    0 / 3
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Cellulitis
         subjects affected / exposed
    0 / 26 (0.00%)
    2 / 67 (2.99%)
    0 / 83 (0.00%)
    0 / 110 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 2
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Sepsis
         subjects affected / exposed
    0 / 26 (0.00%)
    0 / 67 (0.00%)
    2 / 83 (2.41%)
    0 / 110 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 2
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Cystitis
         subjects affected / exposed
    0 / 26 (0.00%)
    0 / 67 (0.00%)
    1 / 83 (1.20%)
    0 / 110 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Diverticulitis
         subjects affected / exposed
    0 / 26 (0.00%)
    0 / 67 (0.00%)
    1 / 83 (1.20%)
    0 / 110 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Escherichia urinary tract infection
         subjects affected / exposed
    0 / 26 (0.00%)
    0 / 67 (0.00%)
    1 / 83 (1.20%)
    0 / 110 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Groin abscess
         subjects affected / exposed
    0 / 26 (0.00%)
    0 / 67 (0.00%)
    1 / 83 (1.20%)
    0 / 110 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Urosepsis
         subjects affected / exposed
    0 / 26 (0.00%)
    0 / 67 (0.00%)
    1 / 83 (1.20%)
    0 / 110 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Urinary tract infection
         subjects affected / exposed
    0 / 26 (0.00%)
    0 / 67 (0.00%)
    0 / 83 (0.00%)
    2 / 110 (1.82%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 2
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Metabolism and nutrition disorders
    Hyperglycaemia
         subjects affected / exposed
    0 / 26 (0.00%)
    0 / 67 (0.00%)
    0 / 83 (0.00%)
    1 / 110 (0.91%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Hyponatraemia
         subjects affected / exposed
    0 / 26 (0.00%)
    0 / 67 (0.00%)
    0 / 83 (0.00%)
    1 / 110 (0.91%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Frequency threshold for reporting non-serious adverse events: 5%
    Non-serious adverse events
    Zimura 1 mg Zimura 2 mg (Combined part 1 + part 2) Zimura 4 mg Sham (Combined part 1 + part 2)
    Total subjects affected by non serious adverse events
         subjects affected / exposed
    13 / 26 (50.00%)
    47 / 67 (70.15%)
    66 / 83 (79.52%)
    59 / 110 (53.64%)
    Investigations
    Intraocular pressure increased
         subjects affected / exposed
    1 / 26 (3.85%)
    6 / 67 (8.96%)
    19 / 83 (22.89%)
    1 / 110 (0.91%)
         occurrences all number
    2
    15
    19
    2
    Injury, poisoning and procedural complications
    Fall
         subjects affected / exposed
    0 / 26 (0.00%)
    9 / 67 (13.43%)
    6 / 83 (7.23%)
    7 / 110 (6.36%)
         occurrences all number
    0
    11
    6
    7
    Laceration
         subjects affected / exposed
    0 / 26 (0.00%)
    3 / 67 (4.48%)
    0 / 83 (0.00%)
    3 / 110 (2.73%)
         occurrences all number
    0
    3
    0
    3
    Contusion
         subjects affected / exposed
    0 / 26 (0.00%)
    1 / 67 (1.49%)
    2 / 83 (2.41%)
    2 / 110 (1.82%)
         occurrences all number
    0
    1
    2
    2
    Vascular disorders
    Hypertension
         subjects affected / exposed
    0 / 26 (0.00%)
    1 / 67 (1.49%)
    3 / 83 (3.61%)
    4 / 110 (3.64%)
         occurrences all number
    0
    1
    3
    4
    Nervous system disorders
    Dementia
         subjects affected / exposed
    0 / 26 (0.00%)
    3 / 67 (4.48%)
    0 / 83 (0.00%)
    0 / 110 (0.00%)
         occurrences all number
    0
    3
    0
    0
    Eye disorders
    Conjunctival haemorrhage
         subjects affected / exposed
    2 / 26 (7.69%)
    11 / 67 (16.42%)
    28 / 83 (33.73%)
    13 / 110 (11.82%)
         occurrences all number
    2
    40
    28
    37
    Neovascular age-related macular degeneration
         subjects affected / exposed
    3 / 26 (11.54%)
    9 / 67 (13.43%)
    11 / 83 (13.25%)
    4 / 110 (3.64%)
         occurrences all number
    3
    10
    11
    4
    Conjunctival hyperaemia
         subjects affected / exposed
    0 / 26 (0.00%)
    3 / 67 (4.48%)
    9 / 83 (10.84%)
    4 / 110 (3.64%)
         occurrences all number
    0
    14
    9
    4
    Punctate keratitis
         subjects affected / exposed
    0 / 26 (0.00%)
    4 / 67 (5.97%)
    6 / 83 (7.23%)
    8 / 110 (7.27%)
         occurrences all number
    0
    7
    6
    9
    Eye pain
         subjects affected / exposed
    0 / 26 (0.00%)
    2 / 67 (2.99%)
    8 / 83 (9.64%)
    3 / 110 (2.73%)
         occurrences all number
    0
    2
    8
    7
    Vitreous detachment
         subjects affected / exposed
    3 / 26 (11.54%)
    2 / 67 (2.99%)
    4 / 83 (4.82%)
    6 / 110 (5.45%)
         occurrences all number
    4
    3
    4
    8
    Cataract
         subjects affected / exposed
    2 / 26 (7.69%)
    4 / 67 (5.97%)
    2 / 83 (2.41%)
    6 / 110 (5.45%)
         occurrences all number
    4
    4
    2
    8
    Visual acuity reduced
         subjects affected / exposed
    0 / 26 (0.00%)
    4 / 67 (5.97%)
    3 / 83 (3.61%)
    8 / 110 (7.27%)
         occurrences all number
    0
    4
    3
    9
    Conjunctival oedema
         subjects affected / exposed
    0 / 26 (0.00%)
    2 / 67 (2.99%)
    5 / 83 (6.02%)
    4 / 110 (3.64%)
         occurrences all number
    0
    7
    5
    17
    Choroidal neovascularisation
         subjects affected / exposed
    1 / 26 (3.85%)
    0 / 67 (0.00%)
    5 / 83 (6.02%)
    3 / 110 (2.73%)
         occurrences all number
    1
    0
    5
    3
    Eye irritation
         subjects affected / exposed
    0 / 26 (0.00%)
    3 / 67 (4.48%)
    2 / 83 (2.41%)
    5 / 110 (4.55%)
         occurrences all number
    0
    6
    2
    6
    Posterior capsule opacification
         subjects affected / exposed
    0 / 26 (0.00%)
    2 / 67 (2.99%)
    0 / 83 (0.00%)
    2 / 110 (1.82%)
         occurrences all number
    0
    2
    0
    2
    Musculoskeletal and connective tissue disorders
    Osteoarthritis
         subjects affected / exposed
    2 / 26 (7.69%)
    1 / 67 (1.49%)
    0 / 83 (0.00%)
    0 / 110 (0.00%)
         occurrences all number
    2
    1
    0
    0
    Spinal column stenosis
         subjects affected / exposed
    2 / 26 (7.69%)
    0 / 67 (0.00%)
    0 / 83 (0.00%)
    2 / 110 (1.82%)
         occurrences all number
    2
    0
    0
    2
    Infections and infestations
    Urinary tract infection
         subjects affected / exposed
    2 / 26 (7.69%)
    7 / 67 (10.45%)
    10 / 83 (12.05%)
    10 / 110 (9.09%)
         occurrences all number
    4
    10
    10
    12
    Nasopharyngitis
         subjects affected / exposed
    1 / 26 (3.85%)
    7 / 67 (10.45%)
    3 / 83 (3.61%)
    5 / 110 (4.55%)
         occurrences all number
    2
    8
    3
    6
    Sinusitis
         subjects affected / exposed
    2 / 26 (7.69%)
    3 / 67 (4.48%)
    3 / 83 (3.61%)
    3 / 110 (2.73%)
         occurrences all number
    2
    3
    3
    4
    Upper respiratory tract infection
         subjects affected / exposed
    1 / 26 (3.85%)
    2 / 67 (2.99%)
    5 / 83 (6.02%)
    2 / 110 (1.82%)
         occurrences all number
    1
    2
    5
    2
    Influenza
         subjects affected / exposed
    0 / 26 (0.00%)
    3 / 67 (4.48%)
    0 / 83 (0.00%)
    2 / 110 (1.82%)
         occurrences all number
    0
    3
    0
    2
    Rhinitis
         subjects affected / exposed
    0 / 26 (0.00%)
    3 / 67 (4.48%)
    0 / 83 (0.00%)
    2 / 110 (1.82%)
         occurrences all number
    0
    3
    0
    4
    Metabolism and nutrition disorders
    Hypokalaemia
         subjects affected / exposed
    0 / 26 (0.00%)
    0 / 67 (0.00%)
    1 / 83 (1.20%)
    2 / 110 (1.82%)
         occurrences all number
    0
    0
    1
    2

    More information

    Close Top of page

    Substantial protocol amendments (globally)

    Were there any global substantial amendments to the protocol? Yes
    Date
    Amendment
    07 Mar 2016
    Amendment A contained clarifications on assessments and inclusion/exclusion criteria.
    16 Oct 2017
    Amendment B added Part 2 including a 4 mg dose, updated primary endpoint and inclusion/exclusion criteria.
    18 Mar 2018
    Amendment C included minor clarifications and administrative items, and added language that no new patients were to be enrolled in Part 1 after Amendment C.

    Interruptions (globally)

    Were there any global interruptions to the trial? No

    Limitations and caveats

    Limitations of the trial such as small numbers of subjects analysed or technical problems leading to unreliable data.
    None reported
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Fri May 02 08:09:01 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA